Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and are Targetable by BET Bromodomain Inhibition.

Hemming ML, Lawlor MA, Andersen JL, Hagan T, Chipashvili O, Scott TG, Raut CP, Sicinska E, Armstrong SA, Demetri GD, Bradner JE.

Cancer Res. 2019 Jan 10. pii: canres.1888.2018. doi: 10.1158/0008-5472.CAN-18-1888. [Epub ahead of print]

PMID:
30630822
2.

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.

Brien GL, Remillard D, Shi J, Hemming ML, Chabon J, Wynne K, Dillon ET, Cagney G, Van Mierlo G, Baltissen MP, Vermeulen M, Qi J, Fröhling S, Gray NS, Bradner JE, Vakoc CR, Armstrong SA.

Elife. 2018 Nov 15;7. pii: e41305. doi: 10.7554/eLife.41305.

3.

Translational insights into gastrointestinal stromal tumor and current clinical advances.

Hemming ML, Heinrich MC, Bauer S, George S.

Ann Oncol. 2018 Oct 1;29(10):2037-2045. doi: 10.1093/annonc/mdy309.

PMID:
30101284
4.

Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome.

Hemming ML, Lawlor MA, Zeid R, Lesluyes T, Fletcher JA, Raut CP, Sicinska ET, Chibon F, Armstrong SA, Demetri GD, Bradner JE.

Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5746-E5755. doi: 10.1073/pnas.1802079115. Epub 2018 Jun 4.

5.

YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy.

Hemming ML, Wagner AJ, Nucci MR, Chiang S, Wang L, Hensley ML, George S.

Gynecol Oncol. 2017 Jun;145(3):531-535. doi: 10.1016/j.ygyno.2017.03.021. Epub 2017 Apr 5.

6.

Identification of beta-secretase (BACE1) substrates using quantitative proteomics.

Hemming ML, Elias JE, Gygi SP, Selkoe DJ.

PLoS One. 2009 Dec 29;4(12):e8477. doi: 10.1371/journal.pone.0008477.

7.

Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements.

Hemming ML, Elias JE, Gygi SP, Selkoe DJ.

PLoS Biol. 2008 Oct 21;6(10):e257. doi: 10.1371/journal.pbio.0060257.

8.

Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.

Hemming ML, Patterson M, Reske-Nielsen C, Lin L, Isacson O, Selkoe DJ.

PLoS Med. 2007 Aug;4(8):e262.

9.
10.
11.

Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein.

Farris W, Leissring MA, Hemming ML, Chang AY, Selkoe DJ.

Biochemistry. 2005 May 3;44(17):6513-25.

PMID:
15850385
12.

Loss of neuropathy target esterase in mice links organophosphate exposure to hyperactivity.

Winrow CJ, Hemming ML, Allen DM, Quistad GB, Casida JE, Barlow C.

Nat Genet. 2003 Apr;33(4):477-85. Epub 2003 Mar 17.

PMID:
12640454

Supplemental Content

Loading ...
Support Center